Can Biologics Manufacturers Face Antitrust Risk For Pointing Out That Biosimilars Are Different? READ MORE
Federal Circuit Affirms Invalidity of Nanopore Sequencing Patents for Failing to Enable, and Affirms Denial of New Trial on the Basis of Defendant’s Allegedly Prejudicial Remarks Regarding the COVID-19 Crisis READ MORE
